116 related articles for article (PubMed ID: 30599218)
1. The antinociceptive effects and molecular mechanisms of ghrelin(1-7)-NH
Wu B; Liu Y; Liu F; Deng Q; Wang J; Han R; Zhang D; Chen J; Wei J
Brain Res Bull; 2019 Mar; 146():112-123. PubMed ID: 30599218
[TBL] [Abstract][Full Text] [Related]
2. Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice.
Zeng P; Li S; Zheng YH; Liu FY; Wang JL; Zhang DL; Wei J
Peptides; 2014 May; 55():103-9. PubMed ID: 24607724
[TBL] [Abstract][Full Text] [Related]
3. Study on the molecular mechanism of antinociception induced by ghrelin in acute pain in mice.
Liu FY; Zhang MM; Zeng P; Liu WW; Wang JL; Yang B; Dai Q; Wei J
Peptides; 2016 Sep; 83():1-7. PubMed ID: 27474249
[TBL] [Abstract][Full Text] [Related]
4. The active fragments of ghrelin cross the blood-brain barrier and enter the brain to produce antinociceptive effects after systemic administration.
Fan BW; Liu YL; Zhu GX; Wu B; Zhang MM; Deng Q; Wang JL; Chen JX; Han RW; Wei J
Can J Physiol Pharmacol; 2021 Oct; 99(10):1057-1068. PubMed ID: 34492212
[TBL] [Abstract][Full Text] [Related]
5. Attenuation of systemic morphine-induced analgesia by central administration of ghrelin and related peptides in mice.
Zeng P; Chen JX; Yang B; Zhi X; Guo FX; Sun ML; Wang JL; Wei J
Peptides; 2013 Dec; 50():42-9. PubMed ID: 24113541
[TBL] [Abstract][Full Text] [Related]
6. In vivo characterization of the effects of ghrelin on the modulation of acute pain at the supraspinal level in mice.
Wei J; Zhi X; Wang XL; Zeng P; Zou T; Yang B; Wang JL
Peptides; 2013 May; 43():76-82. PubMed ID: 23500519
[TBL] [Abstract][Full Text] [Related]
7. In vivo characterization of the effects of human hemokinin-1 and human hemokinin-1(4-11), mammalian tachykinin peptides, on the modulation of pain in mice.
Fu CY; Zhao YL; Dong L; Chen Q; Ni JM; Wang R
Brain Behav Immun; 2008 Aug; 22(6):850-60. PubMed ID: 18262387
[TBL] [Abstract][Full Text] [Related]
8. Supraspinal administration of apelin-13 induces antinociception via the opioid receptor in mice.
Xu N; Wang H; Fan L; Chen Q
Peptides; 2009 Jun; 30(6):1153-7. PubMed ID: 19463749
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of EN-9, a novel chimeric peptide of endomorphin-2 and neuropeptide FF that produces potent antinociceptive activity and limited tolerance.
Wang ZL; Li N; Wang P; Tang HH; Han ZL; Song JJ; Li XH; Yu HP; Zhang T; Zhang R; Xu B; Zhang MN; Fang Q; Wang R
Neuropharmacology; 2016 Sep; 108():364-72. PubMed ID: 26970017
[TBL] [Abstract][Full Text] [Related]
10. Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg psi (CH(2)NH) Arg-NH(2), in mice.
Hiramatsu M; Inoue K; Ambo A; Sasaki Y; Kameyama T
Br J Pharmacol; 2001 Apr; 132(8):1948-56. PubMed ID: 11309268
[TBL] [Abstract][Full Text] [Related]
11. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
[TBL] [Abstract][Full Text] [Related]
12. Identification of opioid receptor subtypes in antinociceptive actions of supraspinally-administered mitragynine in mice.
Thongpradichote S; Matsumoto K; Tohda M; Takayama H; Aimi N; Sakai S; Watanabe H
Life Sci; 1998; 62(16):1371-8. PubMed ID: 9585164
[TBL] [Abstract][Full Text] [Related]
13. Involvement of spinal release of α-neo-endorphin on the antinociceptive effect of TAPA.
Mizoguchi H; Kon-No T; Watanabe H; Watanabe C; Yonezawa A; Sato T; Sakurada T; Sakurada S
Peptides; 2013 Dec; 50():139-44. PubMed ID: 24126280
[TBL] [Abstract][Full Text] [Related]
14. A Tyr-W-MIF-1 analog containing D-Pro2 discriminates among antinociception in mice mediated by different classes of mu-opioid receptors.
Nakayama D; Watanabe C; Watanabe H; Mizoguchi H; Sakurada T; Sakurada S
Eur J Pharmacol; 2007 Jun; 563(1-3):109-16. PubMed ID: 17343845
[TBL] [Abstract][Full Text] [Related]
15. Selective antagonism by naloxonazine of antinociception by Tyr-D-Arg-Phe-beta-Ala, a novel dermorphin analogue with high affinity at mu-opioid receptors.
Sakurada S; Takeda S; Sato T; Hayashi T; Yuki M; Kutsuwa M; Tan-No K; Sakurada C; Kisara K; Sakurada T
Eur J Pharmacol; 2000 Apr; 395(2):107-12. PubMed ID: 10794815
[TBL] [Abstract][Full Text] [Related]
16. Possible involvement of mu1-opioid receptors in the fentanyl- or morphine-induced antinociception at supraspinal and spinal sites.
Narita M; Imai S; Itou Y; Yajima Y; Suzuki T
Life Sci; 2002 Apr; 70(20):2341-54. PubMed ID: 12150199
[TBL] [Abstract][Full Text] [Related]
17. Role of opioid receptors in the spinal antinociceptive effects of neuropeptide FF analogues.
Gouardères C; Jhamandas K; Sutak M; Zajac JM
Br J Pharmacol; 1996 Feb; 117(3):493-501. PubMed ID: 8821539
[TBL] [Abstract][Full Text] [Related]
18. Interaction between the mu-agonist dermorphin and the delta-agonist [D-Ala2, Glu4]deltorphin in supraspinal antinociception and delta-opioid receptor binding.
Negri L; Improta G; Lattanzi R; Potenza RL; Luchetti F; Melchiorri P
Br J Pharmacol; 1995 Dec; 116(7):2931-8. PubMed ID: 8680727
[TBL] [Abstract][Full Text] [Related]
19. Supraspinal antinociceptive effect of apelin-13 in a mouse visceral pain model.
Lv SY; Qin YJ; Wang NB; Yang YJ; Chen Q
Peptides; 2012 Sep; 37(1):165-70. PubMed ID: 22732665
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
